Impact of hepatitis B core antibody (anti HBc) seropositivity on interferon/ribavirin treatment response in patients with chronic hepatitis C

Ibrahim Biyikoglu; Levent Filik; Dilek Oguz; Bahattin Cicek; Birhan Yilmaz; Emin Altiparmak

Impact of hepatitis B core antibody (anti HBc) seropositivity on interferon/ribavirin treatment response in patients with chronic hepatitis C

Bratisl Lek Listy. 2007;108(2):65-9.

Authors

Ibrahim Biyikoglu¹, Levent Filik, Dilek Oguz, Bahattin Cicek, Birhan Yilmaz, Emin Altiparmak

Affiliation

¹ Department of Gastroenterology, Ankara Education and Research Hospital, Ankara, Turkey.

PMID: 17685004

Abstract

AntiHBc seropositivity among patients with chronic HCV infection is not a rare entity (57.14 %). We observed that antiHBc antibody seropositivity does not have a significant impact on treatment responses to interferon/ribavirin therapy in patients for chronic HCV infection in contrast to some reports in the literature (Tab. 6, Ref. 39) Full Text (Free, PDF) www.bmj.sk.

MeSH terms

Antiviral Agents / administration & dosage*
Drug Therapy, Combination
Female
Hepatitis B Antibodies / blood*
Hepatitis C, Chronic / drug therapy*
Hepatitis C, Chronic / immunology
Humans
Interferon alpha-2
Interferon-alpha / administration & dosage*
Male
Middle Aged
Recombinant Proteins
Ribavirin / administration & dosage*

Substances

Antiviral Agents
Hepatitis B Antibodies
Interferon alpha-2
Interferon-alpha
Recombinant Proteins
Ribavirin